Search

Author/Creator van Wijk, M

2. DOP67 First-line infliximab is cost-effective compared to conventional treatment in paediatric Crohn's Disease – Results from the TISKids study. (21st January 2022)

Authors:
Vuijk, S; Jongsma, M; Hoeven, B; Cozijnsen, M; van Pieterson, M; de Meij, T; Norbruis, O; Groeneweg, M; Wolters, V; van Wering, H; Hummel, T; Stapelbroek, J; van der Feen, C; van Rheenen, P; van Wijk, M; Teklenburg, S; Poleij, M; Escher, J; de Ridder, L
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i111
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P448 Long term effectiveness of first-line infliximab treatment compared to conventional treatment in paediatric moderate-to-severe Crohn's disease – an update from the TISKids study. (30th January 2023)

Authors:
Vuijk, S; Jongsma, M; Cozijnsen, M; van Pieterson, M; de Meij, T; Norbruis, O; Groeneweg, M; Wolters, V; van Wering, H; Hojsak, I; Kolho, K L; Hummel, T; Stapelbroek, J; van der Feen, C; van Rheenen, P; van Wijk, M; Teklenburg, S; Escher, J; de Ridder, L
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i579
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗